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Angiogenesis is regulated by the balance between pro- and antiangiogenic factors. Vascular endothelial growth factor (VEGF), acting
via the receptors VEGFR-1 and VEGFR-2, is a key mediator of tumour angiogenesis. The soluble form of the VEGF receptor-1
(sVEGFR-1) is an important negative regulator of VEGF-mediated angiogenesis. The majority of breast cancers are oestrogen
dependent, but it is not fully understood how oestrogen and the antioestrogen, tamoxifen, affect the balance of angiogenic factors.
Angiogenesis is a result of the interplay between cancer and endothelial cells, and sex steroids may exert effects on both cell types. In
this study we show that oestradiol decreased secreted sVEGFR-1, increased secreted VEGF, and decreased the ratio of sVEGFR-1/
VEGF in MCF-7 human breast cancer cells. The addition of tamoxifen opposed these effects. Moreover, human umbilical vein
endothelial cells (HUVEC) incubated with supernatants from oestradiol-treated MCF-7 cells exhibited higher VEGFR-2 levels than
controls. In vivo, MCF-7 tumours from oestradiolþtamoxifen-treated nude mice exhibited decreased tumour vasculature. Our
results suggest that tamoxifen and oestradiol exert dual effects on the angiogenic environment in breast cancer by regulating cancer
cell-secreted angiogenic ligands such as VEGF and sVEGFR-1 and by affecting VEGFR-2 expression of endothelial cells.
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Vascular endothelial growth factor (VEGF) is a key mediator of
tumour angiogenesis, including neovascularisation in human
breast cancer (Folkman, 1995). Vascular endothelial growth factor
is known to exert its angiogenic effects via two tyrosine kinase
receptors, VEGFR-1 (flt-1) and VEGFR-2 (flk-1/KDR) (Ferrara,
1999; Neufeld et al, 1999). Knockout experiments have demon-
strated that both VEGFR-1 and VEGFR-2 are crucial for normal
development of the embryonic vasculature (Fong et al, 1995;
Shalaby et al, 1995). Whereas VEGFR-2 appears to mediate
differentiation, migration, and proliferation of endothelial cells,
VEGFR-1 seems to regulate maintenance of blood vessels in later
developmental stages (Hanahan, 1997). In addition, a naturally
occurring soluble form of VEGFR-1 has been identified (Shibuya
et al, 1990; Kendall and Thomas, 1993). This alternatively spliced
variant of VEGFR-1 with a unique C-terminal extension of 31
residues binds VEGF with high affinity (Kendall and Thomas,
1993). Recombinant sVEGFR-1 has been found to bind all VEGF
isoforms and to inhibit endothelial cell proliferation induced by
VEGF (Kendall et al, 1996). Although the exact physiological role
and mechanism of this receptor is yet unknown, it is thought that
sVEGFR-1 exerts biological activity in the extracellular space,
possibly by sequestering VEGF and limiting its bioavailability
(Hornig and Weich, 1999).
It has been suggested that sVEGFR-1 may be an important
negative regulator of VEGF in breast cancer (Toi et al, 2002).
Breast cancer patients have been found to have significantly higher
plasma levels of VEGF and significantly lower plasma levels of
sVEGFR-1 compared to healthy controls (Caine et al, 2003).
Moreover, the expression of sVEGFR-1 has been demonstrated in
breast tumour tissues, and it has been described that the ratio of
sVEGFR-1 to VEGF is a strong prognostic indicator of disease-free
and overall survival in breast cancer patients (Toi et al, 2002;
Bando et al, 2005).
The predominant localisation of VEGFR-2 has been shown by
immunohistochemistry-based analysis to be in endothelial cells,
yet expression has also been identified in epithelial cells in breast
cancer (de Jong et al, 1998; Kranz et al, 1999; Ryden et al, 2003).
In addition, it has been shown that the expression of activated
VEGFR-2 is higher in malignant breast tissue as compared to
neighbouring non-neoplastic regions (Kranz et al, 1999).
The majority of primary breast tumours are oestrogen-
dependent, and tamoxifen is the most commonly used antioestro-
gen therapy today. Numerous animal models of breast cancer have
previously demonstrated a proangiogenic effect of oestrogens and
an antiangiogenic effect of tamoxifen in vivo (Haran et al, 1994;
Lindner and Borden, 1997; Guo et al, 2002; Dabrosin et al, 2003a,b;
Garvin and Dabrosin, 2003; Elkin et al, 2004). We have previously
shown that oestradiol increases extracellular levels of VEGF while
tamoxifen inhibits the secretion of VEGF in breast cancer in vivo
(Garvin and Dabrosin, 2003). However, very little is known about
the effects of oestradiol and tamoxifen on VEGF receptors and the
angiogenic microenvironment in breast cancer. In this study, we
have investigated the effects of oestradiol and tamoxifen on
sVEGFR-1 and VEGFR-2 in human cell lines in vitro and a mouse
model of breast cancer in vivo. In addition, we have explored the
effects of oestradiol and tamoxifen on endothelial cell expression
of VEGF and VEGFR-2.
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sMATERIALS AND METHODS
Cells and culture conditions
MCF-7 cells (ERþ and PRþ; ATCC, Manassas, VA, USA) were
cultured in Dulbecco’s modified Eagle’s medium without phenol
red supplemented with 2mM glutamine, 50IUml
 1 penicillin-G,
50mgml
 1 streptomycin, and 10% foetal bovine serum (FBS) at
371C in a humidified atmosphere containing 5% CO2. Cell culture
media and additives were obtained from GIBCO, Paisley, UK if not
otherwise stated. Prior to experiments, cells were trypsinised
(0.05% trypsin and 0.02% EDTA) and seeded into Petri dishes
(Costar, Cambridge, MA, USA), 10000cellscm
 2. Cells were
incubated for 1 day and thereafter treated with or without 10
 8 M
oestradiol (17b-oestradiol; Apoteket, Umea ˚, Sweden), 10
 6 M
tamoxifen (Sigma, St Louis, MO, USA) or a combination of
oestradiol and tamoxifen. The dose of oestradiol may be
considered physiological, taking into consideration the local
production and accumulation of oestradiol in human breast
tumours in vivo (van Landeghem et al, 1985; Vermeulen et al,
1986; Pasqualini et al, 1996). The concentration of tamoxifen is
equivalent to therapeutic serum concentrations found in breast
cancer patients. Hormones were added to the MCF-7 cultures in
serum-free medium consisting of a 1:1 mixture of nutrient
mixture F-12 (HAM) and Dulbecco’s modified Eagle’s medium
without phenol red supplemented with 10mgml
 1 transferrin
(Sigma), 1mgml
 1 insulin (Sigma), and 0.2mgml
 1 bovine serum
albumin (Sigma). The medium was changed every day. Secreted
VEGF and sVEGFR-1 was quantified in medium collected from
day 7.
Umbilical cords were donated anonymously after informed
consent according to national ethical legislation. Human umbilical
vein endothelial cells (HUVEC) were isolated from freshly
delivered female donor umbilical veins by collegenase digestion
at 371C for 15min according to established methods (Jaffe et al,
1973). Cells were grown in medium consisting of Dulbecco’s
modified Eagle’s medium without phenol red supplemented with
nonessential amino acids, 1.6mM glutamine, 4IUml
 1 penicillin-
G, 4mgml
 1 streptomycin, 4mgml
 1 insulin, 0.01 M HEPES,
0.02mgml
 1 endothelial cell growth factor (ECGF; Roche Diag-
nostics, Bromma, Sweden), 16IEml
 1 heparin (Apoteket, Umea ˚,
Sweden), and 16% FBS and incubated at 371C in a humidified
atmosphere containing 5% CO2. Cells used for experiments were
from passages 2 to 3. In order to eliminate the oestrogen-like
activity present in FBS, the cells were switched 24h before the start
of hormone treatment to growth medium as described above but
containing 16% charcoal-filtered FBS instead of nonfiltered FBS.
For determination of VEGF and VEGFR-2 cells were trypsinised
(0.05% trypsin and 0.02% EDTA) and seeded into Petri dishes
precoated with 0.2% gelatin (Costar, Cambridge, MA, USA),
20000cellscm
 2. Cells were treated with or without 10
 8 M
oestradiol (17b-oestradiol; Apoteket, Umea ˚, Sweden), 10
 6 M
tamoxifen (Sigma, St Louis, MO, USA) or a combination of
oestradiol and tamoxifen. The medium was changed every day. At
3 days was chosen for the duration of treatment with MCF-7
supernatants due to the shorter survival time of HUVEC without
the medium supplements described above. Secreted VEGF was
quantified in medium collected from day 3. For experiments with
conditioned medium, MCF-7 cell supernatants from oestradiol,
tamoxifen, and control groups collected from days 1, 2, and 3 were
added to HUVEC daily. Supernatants from MCF-7 cells were
collected from dishes with equivalent cell counts in all treatment
groups.
Quantification of VEGF, sVEGFR-1, and VEGFR-2
Cell culture media and cell lysates were analyzed for VEGF,
sVEGFR-1, and VEGFR-2 using commercial quantitative immuno-
assay kits for human VEGF (QuantGlo, human VEGF; R&D
systems, Abingdon, UK), human sVEGFR-1 (Quantikine, human
sVEGFR-1; R&D systems, Abingdon, UK), or human VEGFR-2
(Quantikine, human VEGFR-2; R&D systems, Abingdon, UK)
without preparation. Following the removal of cell medium, the
cells were washed with PBS, frozen in  201C and thawed three
times, diluted in PBS, and sonicated for 10s. Protein content was
determined using Bio-Rad DC Protein Assay (Bio-Rad, Sundbyberg,
Sweden). According to the manufacturer, the VEGF kit measures
the VEGF 165 and 121 isoforms and the minimum detectable dose
is less than 1.76pgml
 1, intra-assay and inter-assay precision
3–8%. The minimum detectable dose is 5.01pgml
 1 for the
sVEGFR-1 kit and 4.6pgml
 1 for the VEGFR-2 kit according to the
manufacturer. The intra-assay and inter-assay precision for these
kits are 3–8 and 3–7%, respectively. All three kits are designed to
eliminate interference by soluble receptors or ligands and other
binding proteins. The sVEGFR-1 kit detects both VEGFR-1 and
sVEGFR-1. For all experiments n equals the total number of dishes
analyzed per treatment arm from repeated experiments as
specified in the figure legends.
Animals and oophorectomy of mice
Female athymic mice (6–8 weeks old) were purchased from M&B,
Denmark. They were housed in a pathogen-free isolation facility
with a light/dark cycle of 12/12h and fed with rodent chow and
water ad libitum. The Linko ¨ping University animal ethics research
board approved all animal work, and the in vivo procedures
used were fully consistent with the animal use guidelines of the
UKCCCR (Workman et al, 1998). Mice were anesthetised with
i.p. injections of ketamine/xylazine, oophorectomised (OVX), and
3-mm pellets containing 17 b-oestradiol, 0.18mg60-d
 1 release, or
placebo pellets (Innovative Research of America, Sarasota, Florida,
USA) were implanted subcutaneously in the animal’s back 7 days
before tumour induction. The pellets provide continuous release of
oestradiol at serum concentrations of 150–250pM, confirmed
previously by serum analysis(Dabrosin et al, 2003b), which is in
the range of physiologic levels during the estrous cycle in mice. At
1 week after surgery, MCF-7 cells (5 10
6 cells in 200ml PBS) were
injected s.c. on the right hind side flank. Tumour volume was
determined by measuring length, width, and depth of the tumour
every 5 days using a caliper. At a tumour size of approximately
300mm
3 (approximately 6–7 weeks after tumour-cell injection),
the mice were divided into two subgroups, n¼5–8 in each group.
One group continued with the oestradiol treatment only, while
tamoxifen (1mg/every two days s.c.) was added to the oestradiol
treatment for 2 weeks in the other group. MCF-7 tumours are
dependent on oestradiol for growth in nude mice (Shafie, 1980).
Therefore, it was not possible to include an untreated control
group or a tamoxifen-alone group in the experimental design.
Immunohistochemistry of tumour sections
Formalin-fixed, paraffin embedded tumours were sectioned,
deparaffinised and subjected to anti-human VEGFR-1 immuno-
histochemistry (goat anti-human VEGFR-1, dilution 1:10, R&D
systems) or anti-von Willebrand’s factor (rabbit anti-human von
Willebrand; dilution 1:1000, DakoCytomation). The anti-human
VEGFR-1 antibody is specific for the extracellular domain of
rhVEGFR-1 and detects both VEGFR-1 and sVEGFR-1. Sections
were counterstained with Mayer’s hematoxylin. Negative controls
did not show staining. VEGFR-1 scoring was conducted in a
blinded manner. The whole material, all sections, was first scanned
to determine the range of intensity of the staining. The intensity
of VEGFR-1 staining in each section was thereafter scored as
weakly or strongly positive in 10 high power fields ( 200)
examined in sections from three different tumours in each group.
Vessel quantification of tumour sections was performed as
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spreviously described using a Nikon microscope equipped with a
digital camera (Schor et al, 1998). In a blinded manner, the section
was first scanned and three hot-spots were selected for vessel area
quantification ( 200). Three different tumours in each group
were measured. The percentage of area with positive staining for
von Willebrand’s factor was assessed using Easy Image Measure-
ment software (Bergstrom Instruments). Tumour sections were
also subjected to H&E staining.
Statistics
The values represent the mean 7 SEM. Statistical analyses were
performed with Student’s t-test, ANOVA with Fisher’s post hoc
test, and Fisher’s exact test where appropriate.
RESULTS
After 7 days of hormone exposure, a significantly higher level
of secreted sVEGFR-1 was detected in MCF-7 cells treated with
tamoxifen as compared to control cells (Po0.01; Figure 1A)
whereas oestradiol-treatment decreased sVEGFR-1 levels (Po0.05
as compared to control cells; Figure 1A). In line with our previous
studies (Garvin and Dabrosin, 2003), the combination of tamoxifen
and oestradiol significantly decreased the secretion of VEGF
(Po0.05 as compared to oestradiol-treated cells) while oestradiol
significantly increased secreted VEGF (Po0.01 as compared
to controls; Figure 1B). Extracellular levels of VEGF in pgmg
 1
protein ranged from approximately 500pgmg
 1 protein in tam-
oxifen-treated cell medium to 1500pgmg
 1 protein in oestradiol-
treated cell medium.
Likewise, levels of cell-associated sVEGFR-1/VEGFR-1 were
significantly higher in tamoxifen-treated MCF-7 cells and signi-
ficantly lower in oestradiol-treated cells; cell-associated sVEGFR-1/
VEGFR-1 levels were 8407300% of control in the tamoxifen
group (Po0.01 compared to control cells, 10075%), 6979% in
the oestradiol group (Po0.05 compared to control cells), and
150727% in the oestradiolþtamoxifen group. In the light of a
recent report that different types of lysis buffers affect measure-
ments of sVEGFR-1 (Bando et al, 2005), it may be noted that no
lysis buffer was used in this experiment and all treatment groups
were prepared in the same manner.
The ratio between sVEGFR-1 and VEGF (in percent of control)
was calculated in order to gain better insight into the biological
relevance of sex steroid effects on the angiogenic environment.
The extracellular sVEGFR-1/VEGF ratio in MCF-7 cell medium
following 7 days of tamoxifen treatment was approximately
nine times greater than that of control cells, while the ratio in
oestradiol-treated cells was nearly one-third that of controls. The
combination of oestradiol and tamoxifen yielded a ratio approxi-
mately equivalent to that of control cells (Figure 1C). This pattern
was also observed in cell lysates, although to a slightly lesser
extent, with a five times greater sVEGFR-1/VEGF ratio in tam-
oxifen-treated cells as compared to controls after 7 days treatment.
The ratio in oestradiol-treated cells was again approximately one-
third of that of controls. It has been suggested that each subunit
of dimeric VEGF binds one molecule of sVEGFR-1 (Kendall
and Thomas, 1993). Calculating the molar sVEGFR-1/VEGF ratio
based on nmolmg
 1 protein revealed a similar pattern, with a
proangiogenic effect on the ratio by oestradiol and an antiangio-
genic effect by tamoxifen; the ratio in oestradiol-treated cells was
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Figure 1 Extracellular sVEGFR-1, VEGF, and sVEGFR-1/VEGF ratio after
hormone exposure of MCF-7 cells in culture. MCF-7 cells were cultured
without hormones (C) or in the presence of oestradiol (E2; 10
 8 M),
tamoxifen (T; 10
 6 M), or a combination of E2þT for 7 days. (A) sVEGFR-
1 in cell culture media measured using ELISA (n¼6–8 in each group, four
separate experiments; **Po0.01, *Po0.05 as compared with control cells,
#Po0.01 as compared with oestradiol-treated cells). (B) Extracellular
VEGF measured using ELISA (n¼4–5 in each group, two separate
experiments; **Po0.01, *Po0.05 as compared with control cells,
#Po0.05 as compared with oestradiol-treated cells). (C) sVEGFR-1/VEGF
ratio based on extracellular levels of sVEGFR-1 and VEGF measured using
ELISA and expressed as percent of control.
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sapproximately one half of that of controls compared to nearly
double that of controls in tamoxifen-treated cells.
We also investigated the effects of hormone treatment on the
expression of VEGFR-2 in MCF-7 cells. Endogenous levels of
VEGFR-2 were not detectable in MCF-7 cells incubated in
hormone-free medium or with addition of oestradiol, tamoxifen,
or oestradiolþtamoxifen.
VEGF is known to exert its effects by acting on endothelial cells
primarily via VEGFR-2. We therefore set up a series of experi-
ments to investigate the effects of oestradiol and tamoxifen on
HUVEC. In the first set of experiments we treated HUVEC
with oestradiol, tamoxifen, or a combination of the two and
measured cellular expression of VEGFR-2. We detected low levels
of VEGFR-2 in HUVEC and found no difference in expression
levels in hormone-treated cells compared to controls (mean
1371.9pgmg
 1 protein for all treatment groups).
In a tumour, endothelial cells are exposed to and affected
by products secreted by cancer cells. We therefore set up a
second set of experiments and treated HUVEC with cell culture
media collected from hormone-treated MCF-7 cells. We found that
VEGFR-2 was upregulated in all groups exposed to conditioned
media from MCF-7 cells compared to hormone-treated HUVEC.
Human umbilical vein endothelial cells exposed to conditioned
media from oestradiol-stimulated MCF-7 cells exhibited signi-
ficantly higher levels of VEGFR-2 as compared to control cells
incubated with media from nonhormone treated MCF-7 cells
(Po0.05; Figure 2).
Low levels of extracellular VEGF were detected in HUVEC
supernatants with no differences observed after addition of
hormones (mean 0.9470.27pgmg
 1 protein for all treatment
groups). No significant differences were detected in the secretion
of VEGF by HUVEC following incubation with conditioned media
from hormone-treated MCF-7 cells (data not shown).
Our in vitro results revealing higher levels of cell-associated
sVEGFR-1/VEGFR-1 in oestradiolþtamoxifen treated cells com-
pared with oestradiol alone prompted further investigation into
the effects of oestradiol and tamoxifen on intratumoral levels
of sVEGFR-1/VEGFR-1 in vivo. Immunohistological staining with
anti-VEGFR-1 was performed on tumour sections from solid
MCF-7 tumours. All treatment groups exhibited similar intra-
cellular localisation of sVEGFR-1/VEGFR-1. No differences were
detected between the groups. Representative tumour sections are
shown in Figure 3A and B.
To evaluate the biological relevance of the balance between
sVEGFR-1 and VEGF on tumour vasculature in vivo, we quantified
vessel area in size-matched tumours from hormone-treated nude
mice. Using immunohistological staining with anti-von Will-
ebrand’s factor and quantifying vessel area in a blinded manner,
we observed significantly decreased vessel area on tumour sections
from animals treated with a combination of oestradiolþtamoxifen
compared to oestradiol treatment only (Po0.05; Figure 4C).
Representative tumour sections are shown in Figure 4A and B.
Microscopic sections of the tumours did not reveal any necrotic
areas in either of the treatment groups. Following 2 weeks of treat-
ment, tumours in the oestradiolþtamoxifen group were signi-
ficantly smaller than those in the oestradiol group (566768mm
3
compared to 12667291mm
3; Po0.05). No mice showed signs of
weight loss or deteriorated general condition.
DISCUSSION
In this study we show in breast cancer cells in vitro that oestradiol
decreased extracellular sVEGFR-1 and increased extracellular
VEGF in vitro. The addition of tamoxifen significantly reversed
these effects. The extracellular ratio of sVEGFR-1/VEGF was nine
times higher following tamoxifen treatment alone compared to
control cells. The ratio in oestradiol-treated cells was approxi-
mately one-third that of control cells. Moreover, in HUVEC,
incubation with supernatants from oestradiol-treated MCF-7 cells
resulted in significantly higher cell-associated VEGFR-2 levels as
compared to control cells.
Tamoxifen has been shown to have an antiangiogenic effect
on breast cancer, but the mechanisms of this effect have not been
fully explored. We propose that the antiangiogenic effect of tam-
oxifen could be explained, at least in part, by its effects on VEGF
and sVEGFR-1 as shown in the present study. Oestradiol, on the
other hand, has been shown to exert proangiogenic effects in
breast cancer, mediated in part by its potent effects on VEGF
(Dabrosin et al, 2003a,b). The present study suggests that
oestrogen influences both sVEGFR-1 levels secreted from cancer
cells and VEGFR-2 expression on endothelial cells, resulting in a
net proangiogenic effect. The in vitro data were confirmed by the
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Figure 2 Cell-associated VEGFR-2 after exposure of HUVEC to
hormone-treated MCF-7 cell supernatants in culture. MCF-7 cells were
treated as described in Figure 1. After 24h, the MCF-7 cell supernatants
(C, E2, T, and E2þT groups, respectively) were transferred to untreated
HUVEC and thereafter changed every day. VEGFR-2 was measured in
HUVEC cell lysates using ELISA after 3 days in culture (n¼4–5 in each
group, two separate experiments; *Po0.05 as compared with control
cells).
Figure 3 Immunohistochemistry of VEGFR-1 in tumour sections. Solid
MCF-7 tumours were established in nude mice as described in the
Materials and Methods section. No differences were observed in the
intensity of staining in tumours from the two treatment groups, oestradiol
(E2) and oestradiolþtamoxifen (E2þT). Representative sections from
tumours are shown. (A) Tumour section from an oestradiol-treated
tumour. (B) Tumour section from an oestradiolþtamoxifen-treated
tumour.
Oestrogen decreases and tamoxifen increases sVEGFR-1
S Garvin et al
1008
British Journal of Cancer (2005) 93(9), 1005–1010 & 2005 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
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vivo. Our results are in agreement with a recent study describing
decreased sVEGFR-1 expression in oestrogen-receptor positive cell
lines following treatment with oestradiol (Elkin et al, 2004). In this
study, the oestrogen-mediated decrease in sVEGFR-1 expression in
vitro was accompanied by a significant increase in angiogenesis in
vivo (Elkin et al, 2004).
Although differences in cell-associated sVEGFR-1/VEGFR-1
were observed in vitro in our present study, immunohistological
staining of sVEGFR-1/VEGFR-1 in tumour sections did not reveal
any significant differences between oestradiol and oestradiolþ
tamoxifen-treated animals. The intracellular staining observed is
consistent with previous findings, suggesting that MCF-7 cells
express only sVEGFR-1 and virtually no cell-membrane bound
VEGFR-1 (Elkin et al, 2004). sVEGFR-1 diffuses freely into the
extracellular space where it is suggested to be biologically active
(Hornig and Weich, 1999), and it is uncertain if soluble
extracellular proteins can be detected by immunohistochemical
techniques (Zhang et al, 2000). It is possible that immuno-
histochemistry, considered a semiquantitative method, is not
sensitive enough to detect intracellular differences between treat-
ment groups. A direct measurement of sVEGFR-1 in situ in the
tumour would be a preferable way to investigate sVEGFR-1.
However, due to sVEGFR-1’s large molecular size, the technique of
microdialysis, which we have used in previous studies (Dabrosin
et al, 2003a; Garvin and Dabrosin, 2003), could not be employed to
measure the in vivo levels of sVEGFR-1 in solid tumours.
In this study, we also show that incubation of HUVEC with
supernatants from oestradiol-treated MCF-7 cells resulted in
increased cell-associated VEGFR-2 levels as compared to control
cells. When HUVEC were cultured in regular growth media with
and without hormones added VEGFR-2 was detected at very low
levels. However, when HUVEC were cultured in supernatants from
MCF-7 cells, VEGFR-2 was upregulated in all groups with a
significantly higher level in HUVEC grown in media from
oestrogen-treated cancer cells compared with cancer cell media
without hormones added. It has been demonstrated that VEGF
upregulates the expression of VEGFR-2 in endothelial cells
(Murata et al, 2000). Our results suggest that the excess of
unbound VEGF detected in oestrogen-treated MCF-7 cell super-
natants may contribute to increased expression of VEGFR-2 in
HUVEC. However, the influence of other hormone responsive
factors secreted from hormone-stimulated MCF-7 cells may also
contribute to higher VEGFR-2 levels. In addition, it has been
demonstrated that HUVEC express oestrogen receptors (Kim-
Schulze et al, 1996; Venkov et al, 1996), thus direct hormonal
effects on HUVEC cannot be excluded although not apparent in
our results. It is unlikely that HUVEC-derived VEGF contributes to
this upregulation, as very low levels of extracellular VEGF were
detected in HUVEC supernatants. Moreover, VEGF secretion by
HUVEC did not appear to be affected by direct hormone treatment
or by incubation with supernatants from hormone-treated MCF-7
cells.
VEGFR-2 was not detected in MCF-7 cells irregardless of the
absence or presence of hormones. Although it has been proposed
that VEGFR-2 expression in breast cancer cells may function as an
autocrine loop in which VEGF regulates growth of cancer cells in
an animal model for breast cancer (Xie et al, 1999), this does not
appear to be the case for MCF-7.
In summary, we show that tamoxifen and oestradiol exert dual
effects on the angiogenic environment in breast cancer by
regulating extracellular levels of important angiogenic factors
secreted by cancer cells as well as by exerting effects on receptor
expression of endothelial cells. Our results suggest an oestrogen-
driven angiogenic switch, explained by the inhibition of sVEGFR-1
and stimulation of VEGF and VEGFR-2, tipping the angiogenic
scale to favour angiogenesis, and possibly contributing to breast
carcinoma progression. Tamoxifen, on the other hand, tips the
balance to favor angiogenic inhibition. We emphasise the
importance of investigating the regulation of proteins where they
are biologically active, in the extracellular space in the case of
VEGF and sVEGFR-1. Moreover, the results of this study illustrate
the importance of the interaction between tumour cells and local
microenvironment in regulating angiogenesis and the critical role
of sex steroids in this process.
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stained with anti-von Willebrand’s factor. Representative tumour sections
from the oestradiol and the oestradiolþtamoxifen-treated groups are
shown in (A) and (B), respectively. Examples of positively stained vessels
are marked with arrows. (C) Tumour vessel area based on positive tumour
staining for von Willebrand’s factor and conducted in a blinded manner.
Vessel area in percent was measured from three hot-spots from three
different tumours in each group (*Po0.05).
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